The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: Protocol for a randomised, double-blinded, placebo-controlled trial

BMJ Open

Volumn 7, Issue 5, 2017, Pages

  Larsen, Emil List ^a,b   Cejvanovic, Vanja ^a,b,c   Kjær, Laura Kofoed ^a,b,c   Vilsbøll, Tina ^b   Knop, Filip Krag ^b   Rungby, Jørgen ^b   Poulsen, Henrik Enghusen ^a,b,c  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

8 oxo 7 8 dihydro 2 deoxyguanosine; 8 oxo 7 8 dihydroguanosine; Diabetes Mellitus; Empagliflozin; Oxidative modifications; Oxidative Nucleic Acid Modifications; Type 2

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 OXO 7,8 DIHYDROGUANOSINE; EMPAGLIFLOZIN; FERRITIN; GUANOSINE; HEMOGLOBIN A1C; IRON; MALONALDEHYDE; PLACEBO; TRANSFERRIN; UNCLASSIFIED DRUG; 8-HYDROXYGUANOSINE; 8-OXO-7-HYDRODEOXYGUANOSINE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; DEOXYGUANOSINE; GLUCOSIDE; NUCLEIC ACID; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FERRITIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; LIPID PEROXIDATION; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; URINE SAMPLING; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DENMARK; METHODOLOGY; MIDDLE AGED; STATISTICAL MODEL; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BENZHYDRYL COMPOUNDS; BIOMARKERS; DENMARK; DEOXYGUANOSINE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; GLUCOSIDES; GUANOSINE; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; NUCLEIC ACIDS; OXIDATIVE STRESS; RESEARCH DESIGN; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85018901127     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-014728     Document Type: Article

References (40)

1. World Health Organization. Global Report on Diabetes. 2016 http://apps. who. int/iris/bitstream/10665/204871/1/9789241565257-eng. pdf
2. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 19 million people. Lancet Diabetes Endocrinol 2015;3:105-13.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42.
4. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
5. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98.
6. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: A retrospective cohort study. Lancet 2010;375:481-9.
7. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
8. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35.
9. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42.
10. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 Diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57.
11. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
12. Broedbaek K, Weimann A, Stovgaard ES, et al. Urinary 8-oxo-7, 8-dihydro-2-deoxyguanosine as a biomarker in type 2 diabetes. Free Radic Biol Med 2011;51:1473-9.
13. Broedbaek K, Siersma V, Henriksen T, et al. Urinary markers of nucleic acid oxidation and long-Term mortality of newly diagnosed type 2 diabetic patients. Diabetes Care 2011;34:2594-6.
14. Broedbaek K, Siersma V, Henriksen T, et al. Association between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes: A population-based cohort study. Diabetes Care 2013;36:669-76.
15. Glintborg B, Weimann A, Kensler TW, et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: unaltered oxidative biomarkers. Free Radic Biol Med 2006;41:1010-4.
16. Broedbaek K, Henriksen T, Weimann A, et al. Long-Term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: An Irbesartan in patients with type 2 diabetes and microalbuminuria (IRMA 2) substudy. Diabetes Care 2011;34:1192-8.
17. Poulsen HE, Specht E, Broedbaek K, et al. RNA modifications by oxidation: A novel disease mechanism? Free Radic Biol Med 2012;52:1353-61.
18. Rasmussen ST, Andersen JT, Nielsen TK, et al. Simvastatin and oxidative stress in humans: A randomized, double-blinded, placebo-controlled clinical trial. Redox Biol 2016;9:32-8.
19. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502.
20. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and mortality in type 2 Diabetes. N Engl J Med 2015;373:2117-28.
21. Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and Cardiovascular risk: lessons learned from the EMPA-REG OUTCOME Study. Diabetes Care 2016;39:717-25.
22. Tikkanen I, Chilton R, Johansen OE. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. Curr Opin Nephrol Hypertens 2016;25:81-6.
23. Sattar N, McLaren J, Kristensen SL, et al. SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 2016.
24. Oelze M, Kröller-Schön S, Welschof P, et al. The sodium-glucose co-Transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One 2014;9:e112394-13.
25. Cheng ST, Chen L, Li SY, et al. The effects of Empagliflozin, an SGLT2 Inhibitor, on pancreatic β-Cell Mass and Glucose Homeostasis in type 1 Diabetes. PLoS One 2016;11:e0147391-12.
26. Nishimura R, Tanaka Y, Koiwai K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol 2015;14:11.
27. Frijhoff J, Winyard PG, Zarkovic N, et al. Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal 2015;23:1144-70.
28. Broedbaek K, Poulsen HE, Weimann A, et al. Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic Biol Med 2009;47:1230-3.
29. Stroh M, Swerdlow RH, Zhu H. Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): A paradigm worth exploring. Biochem Pharmacol 2014;88:573-83.
30. Poulsen HE, Nadal LL, Broedbaek K, et al. Detection and interpretation of 8-oxodG and 8-oxoGua in urine, plasma and cerebrospinal fluid. Biochim Biophys Acta 2014;1840:801-8.
31. Lykkesfeldt J. Determination of malondialdehyde as dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: comparison with ultraviolet-visible spectrophotometry. Clin Chem 2001;47:1725-7.
32. Chan A-W, Tetzlaff JM, Altman DG, et al. Research and Reporting methods annals of internal medicine SPIRIT 2013 Statement : defining Standard Protocol items for clinical trials. 2015;1.
33. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.
34. Jardiance. http://pro. medicin. dk/Medicin/Praeparater/7463 (accessed 10 Jun 2016).
35. European-Commision. Good manufacturing practice. Medicinal products for human and vetrinary use. Annex 13. Investigational medicinal products. 2010;4.
36. Larsen EL, Cejvanovic V, Kjaer LK, et al. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. Br J Clin Pharmacol 2017.
37. Loft S, Vistisen K, Ewertz M, et al. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis 1992;13:2241-7.
38. Weimann A, Broedbaek K, Henriksen T, et al. Assays for urinary biomarkers of oxidatively damaged nucleic acids. Free Radic Res 2012;46:531-40.
39. Lykkesfeldt J. Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta 2007;380:50-8.
40. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical practice E6(R1). ICH Harmon Tripart Guidel 1996.